A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of a Nicotine Mint Lozenge (2 and ) in Smoking Cessation.

What Was Tested

This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).

Cochran-Mantel-Haenszel tests were performed to compare quit rates between active nicotine and placebo separately for the high-dependence and low-dependence strata.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

The primary endpoint was successful smoking cessation at 6 weeks postquit, defined as continuous abstinence from smoking for the 28-day period up to and including the 6-week visit (verified by CO measurement).

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled, multicenter and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

Blinding on both sides kept the participants and researchers unaware of who received Therapeutic nicotine (patch, non-peptide).

Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

More than one site took part, so the participants came from several places.

This was a multicenter, randomized, stratified, double-blind, placebo-controlled, parallel-group study.

What Was Measured

The subject headings attached to it are Logistic Models, Mentha, Nicotine, Nicotinic Agonists, Smoking Cessation, Tobacco Use Cessation Devices and Tobacco Use Disorder.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Journal of addiction medicine), a journal based in Netherlands.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.